United States Patent 9,180,194: Claim Scope, Axiron Patent Landscape, and Generic Entry Risk

U.S. Patent No. 9,180,194 covers a method of raising testosterone blood levels in adult men by applying a non-occlusive testosterone composition to at least one axilla. The independent claim requires testosterone, 40% to 99% by volume of ethanol, isopropanol, or a mixture, and 0.01% to 15% weight/volume of octyl salicylate. The patent is directed to a topical testosterone delivery method rather than a broad composition or device claim.

The patent’s commercial relevance is tied to Axiron testosterone topical solution, originally developed by Acrux and commercialized in the United States by Eli Lilly. Its principal competitive risk comes from alternative testosterone formulations, design-around products that omit octyl salicylate or axillary administration, and generic testosterone topical solutions that do not practice every claim limitation.

What does U.S. Patent 9,180,194 protect?

The patent protects a specific treatment method with five central requirements:

The patient must be an adult male subject in need of increased testosterone.
The composition must be applied to at least one axilla.
Application must be non-occlusive.
The composition must contain testosterone.
The solvent and penetration-enhancer concentrations must fall within the claimed ranges.

The independent claim uses the transitional term “comprising.” That term generally permits additional ingredients, excipients, preservatives, fragrances, permeation enhancers, or other formulation components, provided the accused product still contains every required element.

Claim 1: core infringement elements

Claim element	Scope and commercial significance
Method of increasing testosterone blood level	Requires a treatment method, not merely possession or manufacture of a composition
Adult male subject	Excludes female patients and potentially excludes pediatric use
Subject “in need thereof”	A functional patient-selection limitation
Application to at least one axilla	Covers unilateral or bilateral axillary administration
Non-occlusive application	Excludes use under a patch, sealed dressing, or other occlusive barrier
Testosterone	Does not specify a particular testosterone concentration or ester
40% to 99% v/v volatile solvent	Solvent must fall within the stated volume range
Ethanol, isopropanol, or mixtures	Limits the volatile solvent identity
0.01% to 15% w/v octyl salicylate	Requires the specified penetration enhancer within the claimed range

The claim does not expressly require a pump, a particular dose per actuation, a particular application frequency, a defined testosterone concentration, or a particular commercial container. Those features may appear in related patents, product specifications, or regulatory labeling, but they are not limitations of claim 1 as quoted.

Dependent claims 2 through 6

Claim 2 adds 1% to 5% w/v of a thickener. Claim 3 narrows the thickener to polyvinylpyrrolidone, commonly known as PVP.

Claims 4 and 5 narrow the patient population. Claim 4 covers men suffering from androgen deficiency, while claim 5 requires hypogonadism.

Claim 6 adds a serum testosterone target of 300 to 1000 ng/dL. The supplied text states “ng/dh.” Testosterone levels are ordinarily reported in ng/dL. The enforceable scope depends on the issued patent text and any applicable correction or prosecution-history treatment of that unit.

How broad is the scope of claim 1?

Claim 1 is narrower than a general patent on topical testosterone but broader than a claim limited to Axiron’s exact commercial presentation.

The claim is formulation-specific because octyl salicylate is mandatory. A testosterone gel or solution using another penetration enhancer, such as oleic acid, isopropyl myristate, diethylene glycol monoethyl ether, or a proprietary enhancer, would not literally satisfy the octyl-salicylate limitation.

The claim is also route-specific. A product applied to the shoulders, upper arms, abdomen, thighs, or scrotum would not literally satisfy the requirement for application to at least one axilla. A product applied to the axilla but covered with an occlusive dressing could raise a dispute over the “non-occlusive” limitation.

The solvent range creates another measurable boundary. A formulation containing 39% ethanol by volume would fall outside the literal range if the formulation has no qualifying isopropanol or solvent mixture that brings the total within the claim. A formulation containing 99% or less of the specified volatile solvent remains within the numerical range, subject to the other limitations.

What do claims 2 through 6 add?

The dependent claims create narrower fallback positions.

Claim	Added limitation	Practical effect
2	1% to 5% w/v thickener	Captures viscous or film-forming formulations within the concentration range
3	Thickener is PVP	Narrows claim 2 to a named polymer
4	Patient has androgen deficiency	Limits the medical indication
5	Patient has hypogonadism	Creates a more specific disease-state limitation
6	Serum testosterone of 300 to 1000 ng/dL	Adds a measurable pharmacodynamic outcome and depends on claim 5

Claims 2 and 3 are formulation-focused. Claims 4 through 6 are method-of-treatment claims. The narrower claims may be useful in litigation where a competing product practices axillary testosterone delivery but disputes the breadth of claim 1.

Claim 6 is potentially difficult to enforce in routine commercial settings because proving the serum-level limitation may require patient-specific evidence. A product label or prescribing instruction may support induced-infringement allegations, but direct infringement of a patient-treatment claim generally turns on actual performance of the claimed method.

What patents protect Axiron and related testosterone topical products?

U.S. Patent 9,180,194 belongs to a broader Acrux transdermal testosterone patent family associated with Axiron. Public patent and FDA records identify several related U.S. patents covering transdermal compositions, methods of use, and related formulation features.

Patent	General role in the family	Commercial relevance
U.S. 7,320,691	Earlier transdermal testosterone composition and use claims	Foundational Axiron-related protection
U.S. 8,435,944	Related continuation-family protection	Formulation and method overlap
U.S. 9,180,194	Axillary, non-occlusive testosterone administration method	Directly corresponds to the claims analyzed here
U.S. 9,592,186	Later related family patent	Potentially adds further formulation or use coverage

The exact claim scope differs by patent. A freedom-to-operate review must compare the issued claims of each family member rather than treat the family as a single right. Continuation patents may divide protection among formulation composition, delivery method, patient population, dosing, and product configuration.

When does U.S. Patent 9,180,194 lose exclusivity?

The patent was granted on November 10, 2015. Its patent family traces to a priority date in August 2005. On that basis, the ordinary 20-year patent term would place the nominal expiration in August 2025, subject to any patent-term adjustment, terminal disclaimer, or other USPTO-recorded term modification.

Event	Date or period
Earliest family priority	August 2005
U.S. patent grant	November 10, 2015
Nominal 20-year expiration	August 2025
FDA product associated with the family	Axiron testosterone topical solution
Regulatory category	Small-molecule drug
Biosimilar pathway	Not applicable

The critical commercial question is not only whether Patent 9,180,194 has expired, but whether related patents remained enforceable during the proposed launch period. A generic manufacturer could face Orange Book-listed patents that expire on different dates or that contain overlapping formulation and method claims.

What is the Orange Book status of U.S. Patent 9,180,194?

Patent 9,180,194 has been associated with Axiron in FDA patent-listing records. Orange Book listing is significant because a generic applicant referencing Axiron must address listed patents through a certification under the Hatch-Waxman framework.

A listed patent can generate:

A Paragraph III certification agreeing not to market until patent expiration.
A Paragraph IV certification asserting that the patent is invalid, unenforceable, or not infringed.
A patent-infringement action by the listed patent owner within the statutory period.
A potential 30-month stay of approval, subject to the statutory requirements and litigation posture.

The Orange Book does not itself determine infringement or validity. It identifies patents submitted by the NDA holder and accepted for listing by FDA. Claim interpretation remains a matter for the courts.

Which companies challenged Axiron patents?

Public Axiron-related litigation and generic development activity involved manufacturers seeking approval for testosterone topical solution products. The relevant competitive set has included Perrigo, Actavis/Teva, and other generic developers pursuing testosterone replacement products.

A Paragraph IV analysis must be performed at the ANDA and patent level. A company may challenge one listed patent while certifying to expire on another, and a settlement may resolve litigation without establishing whether the challenged patent is valid or infringed.

For Patent 9,180,194, the main litigation questions would have been:

Whether the proposed generic contains octyl salicylate within 0.01% to 15% w/v.
Whether the proposed label instructs administration to the axilla.
Whether the labeled administration is non-occlusive.
Whether the generic’s solvent system contains ethanol or isopropanol within the claimed range.
Whether the proposed label induces treatment of adult men with hypogonadism.
Whether serum-level language is required by the label or is merely an expected clinical result.

What generic launch risks exist?

Generic entry risk depends on both formulation design and labeling.

High-risk design

A generic product has high exposure if it:

Uses testosterone in an ethanol or isopropanol-rich solution.
Contains octyl salicylate within the claimed range.
Is labeled for application to one or both axillae.
Is applied without an occlusive covering.
Uses PVP at 1% to 5% w/v.
Is labeled for male hypogonadism.

Such a product could practice claims 1 through 5, depending on the exact concentrations and instructions.

Lower-risk design

Risk is reduced where the product:

Uses another penetration enhancer.
Omits octyl salicylate.
Uses a non-axillary administration site.
Uses a transdermal patch or another delivery system.
Uses a solvent outside the claimed range.
Has a label that does not direct use for hypogonadism.

A design-around must be evaluated against all related patents, not only Patent 9,180,194. Removing octyl salicylate may avoid this patent while still implicating another patent covering testosterone delivery or a different enhancer.

Does biosimilar risk apply to Axiron?

No. Testosterone is a small-molecule active pharmaceutical ingredient. Axiron is subject to the ANDA and Hatch-Waxman framework, not the abbreviated biologics license application and biosimilar framework under the Public Health Service Act.

The relevant competitive mechanisms are generic drug approval, Paragraph IV certification, patent litigation, settlement agreements, and product-specific exclusivity. Biosimilar interchangeability, reference-product exclusivity, and the Biologics Price Competition and Innovation Act do not govern this product.

How does this patent compare with competing testosterone estates?

Axiron’s patent estate is differentiated by its axillary delivery route and volatile-solvent formulation. Competing testosterone products use different dosage forms and administration sites.

Product category	Typical delivery site or form	Relationship to Patent 9,180,194
Axillary testosterone solution	Axilla, non-occlusive solution	Closest claim overlap
Shoulder or upper-arm testosterone gel	Shoulders, upper arms, or abdomen	Usually outside the axilla limitation
Testosterone patch	Occlusive or semi-occlusive delivery system	May avoid the non-occlusive limitation
Buccal testosterone	Oral mucosal system	Outside the transdermal claim
Injectable testosterone	Intramuscular or subcutaneous	Outside the claim
Nasal testosterone	Intranasal administration	Outside the claim

The patent is therefore strong against a directly substitutable axillary solution using the claimed enhancer, but less relevant to products that change the administration site, dosage form, or penetration-enhancer system.

What manufacturing and intellectual-property barriers remain?

Manufacturing complexity is moderate. The composition uses common pharmaceutical solvents and a known salicylate penetration enhancer. The main barriers are not necessarily raw-material availability. They are:

Reproducing the required concentration ranges.
Controlling evaporation and delivered dose.
Maintaining content uniformity in a volatile solution.
Demonstrating consistent transdermal absorption.
Establishing bioequivalence to the reference product.
Avoiding the Axiron patent family and other testosterone patents.
Aligning the proposed label with patent certifications.

The commercial barrier is stronger where the product must match Axiron’s delivery site, dosing system, clinical indication, and pharmacokinetic profile. A non-axillary testosterone product may avoid this patent but compete less directly with the reference product.

How strong is the patent estate for Patent 9,180,194?

Patent 9,180,194 has meaningful claim value because it combines route, formulation, enhancer, solvent, and therapeutic-use limitations. The principal strength is the convergence of those limitations around the Axiron product concept.

Its principal weaknesses are narrowness and proof burden:

A competing product can avoid literal infringement by omitting octyl salicylate.
Non-axillary products fall outside the express route limitation.
“Non-occlusive” may require fact-intensive analysis.
Patient-specific blood-level limitations complicate enforcement of claim 6.
The patent’s nominal expiration date materially limits forward-looking exclusivity.

The patent is stronger as a blocking right against a close Axiron substitute than as a broad barrier to the testosterone replacement market.

Key Takeaways

U.S. Patent 9,180,194 covers non-occlusive axillary administration of a testosterone composition.
Claim 1 requires ethanol, isopropanol, or a mixture at 40% to 99% v/v and octyl salicylate at 0.01% to 15% w/v.
Claims 2 and 3 add a thickener, specifically PVP in claim 3.
Claims 4 through 6 narrow the patient population and add hypogonadism and serum-level limitations.
The patent is associated with the Axiron transdermal testosterone patent family.
The nominal patent-term endpoint is August 2025, subject to the official USPTO term calculation.
Generic risk is highest for an axillary testosterone solution using octyl salicylate within the claimed range.
Biosimilar analysis does not apply because testosterone is a small molecule.
A complete launch assessment must review all Axiron-related Orange Book patents and any applicable Paragraph IV litigation or settlement terms.

FAQs

Is octyl salicylate the same as octyl methoxycinnamate?

No. Octyl salicylate, commonly identified as ethylhexyl salicylate, is chemically distinct from octyl methoxycinnamate, also known as octinoxate.

Does Patent 9,180,194 cover testosterone gel applied to the shoulders?

Not on the quoted claims. The claims require application to at least one axilla. A shoulder-applied product may implicate other patents but does not literally meet that route limitation.

Can a generic avoid the patent by removing PVP?

Removing PVP may avoid claims 2 and 3, but it does not avoid claim 1. The generic would still need to assess testosterone, solvent, octyl salicylate, axillary administration, and non-occlusive use.

Does the patent cover injectable testosterone?

No. The quoted claims require application of a transdermal composition to an axilla. Injectable testosterone does not satisfy that limitation.

Does FDA Orange Book listing prove that the patent is valid?

No. Listing identifies a patent submitted in connection with an approved drug. It does not establish validity, enforceability, infringement, or the correct interpretation of the claims.

References

U.S. Patent and Trademark Office. (2015). U.S. Patent No. 9,180,194, Transdermal compositions and methods of use thereof.
U.S. Patent and Trademark Office. (2008). U.S. Patent No. 7,320,691, Transdermal compositions and methods of use thereof.
U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,435,944, Transdermal compositions and methods of use thereof.
U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,592,186, Transdermal compositions and methods of use thereof.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2010). Axiron testosterone topical solution prescribing information.
U.S. Code, 35 U.S.C. §§ 154, 271, 281, 282.
U.S. Code, 21 U.S.C. § 355(j).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eli Lilly And Co	AXIRON	testosterone	SOLUTION, METERED;TRANSDERMAL	022504-001	Nov 23, 2010		DISCN	Yes	No	9,180,194	⤷ Start Trial				A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Australia	2005902902	Jun 3, 2005

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006254742	⤷ Start Trial
Australia	2011202787	⤷ Start Trial
Brazil	PI0611134	⤷ Start Trial
Canada	2610708	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,180,194

Which drugs does patent 9,180,194 protect, and when does it expire?

Summary for Patent: 9,180,194